Faes Farma (FAE.MC) Stock Price

Faes Farma Price

BME·CLOSED
4.52EUR-0.01 (-0.33 %)
Market closed

Over the last 19 years Faes Farma grew revenue by 6.5% annually, reaching 610.46 M EUR. Earnings per share have grown at 8.2% per year over the last 15 years. For Faes Farma, the net margin of 13.0% is down versus 20.7% a few years ago. At today's price the dividend yield works out to roughly 3.96%. The payout ratio is around 70% of earnings. The consensus 12-month price target for Faes Farma is 5.61 EUR, about 24.1% above where the stock trades today. Of 10 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 9% above its 52-week low.

Faes Farma stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Faes Farma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Faes Farma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Faes Farma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Faes Farma Stock Price History
DateFaes Farma Price
8/7/20264.52 EUR
8/6/20264.53 EUR
8/5/20264.51 EUR
8/4/20264.51 EUR
7/31/20264.56 EUR
7/30/20264.51 EUR
7/29/20264.64 EUR
7/28/20264.61 EUR
7/27/20264.61 EUR
7/24/20264.57 EUR
7/23/20264.59 EUR
7/22/20264.55 EUR
7/21/20264.36 EUR
7/20/20264.34 EUR
7/17/20264.36 EUR
7/16/20264.39 EUR
7/15/20264.35 EUR
7/14/20264.35 EUR
7/13/20264.43 EUR
7/10/20264.47 EUR
7/9/20264.53 EUR
7/8/20264.55 EUR
7/7/20264.59 EUR
7/6/20264.56 EUR
7/3/20264.58 EUR
7/2/20264.65 EUR
7/1/20264.55 EUR
6/30/20264.59 EUR
6/29/20264.61 EUR
6/26/20264.62 EUR
6/25/20264.62 EUR
6/24/20264.60 EUR
6/23/20264.65 EUR
6/22/20264.57 EUR
6/19/20264.55 EUR
6/18/20264.57 EUR
6/17/20264.53 EUR
6/16/20264.52 EUR
6/15/20264.55 EUR
6/12/20264.57 EUR
6/11/20264.57 EUR
6/10/20264.49 EUR
6/9/20264.52 EUR
6/8/20264.55 EUR
6/5/20264.63 EUR
6/4/20264.55 EUR
6/3/20264.51 EUR
6/2/20264.55 EUR
6/1/20264.62 EUR
5/29/20264.76 EUR
5/28/20264.72 EUR
5/27/20264.75 EUR
5/26/20264.71 EUR
5/25/20264.67 EUR
5/22/20264.61 EUR
5/21/20264.62 EUR
5/20/20264.55 EUR
5/19/20264.53 EUR
5/18/20264.55 EUR
5/15/20264.59 EUR
5/14/20264.64 EUR
5/13/20264.64 EUR
5/12/20264.66 EUR
5/11/20264.78 EUR
5/8/20264.82 EUR
5/7/20264.86 EUR
5/6/20264.91 EUR
5/5/20264.88 EUR
5/4/20264.88 EUR
4/30/20264.86 EUR
4/29/20264.74 EUR
4/28/20264.79 EUR
4/27/20264.78 EUR
4/24/20264.80 EUR
4/23/20264.86 EUR
4/22/20264.90 EUR
4/21/20264.93 EUR
4/20/20264.91 EUR
4/17/20264.91 EUR
4/16/20264.89 EUR
4/15/20264.91 EUR
4/14/20264.94 EUR
4/13/20264.90 EUR
4/10/20264.89 EUR
4/9/20264.82 EUR
4/8/20264.83 EUR
4/7/20264.66 EUR
4/2/20264.70 EUR
4/1/20264.74 EUR
3/31/20264.66 EUR
3/30/20264.63 EUR
3/27/20264.58 EUR
3/26/20264.56 EUR
3/25/20264.59 EUR
3/24/20264.49 EUR
3/23/20264.47 EUR
3/20/20264.42 EUR
3/19/20264.47 EUR
3/18/20264.51 EUR
3/17/20264.49 EUR
3/16/20264.50 EUR
3/13/20264.56 EUR
3/12/20264.63 EUR
3/11/20264.69 EUR
3/10/20264.70 EUR
3/9/20264.69 EUR
3/6/20264.74 EUR
3/5/20264.76 EUR
2/26/20264.88 EUR
2/25/20265.00 EUR
2/23/20264.99 EUR
2/20/20265.13 EUR
2/19/20265.19 EUR
2/18/20265.18 EUR
2/17/20265.24 EUR
2/16/20265.25 EUR
2/13/20265.33 EUR
2/12/20265.30 EUR
2/11/20265.27 EUR
2/10/20265.27 EUR
2/9/20265.22 EUR
2/6/20265.19 EUR
2/5/20265.24 EUR
2/4/20265.26 EUR
2/3/20265.23 EUR
2/2/20265.23 EUR
1/30/20265.23 EUR
1/29/20265.19 EUR
1/28/20265.13 EUR
1/27/20265.11 EUR
1/26/20265.11 EUR
1/23/20265.11 EUR
1/22/20265.06 EUR
1/21/20264.93 EUR
1/20/20264.95 EUR
1/19/20265.09 EUR
1/16/20265.11 EUR
1/15/20265.13 EUR
1/14/20265.17 EUR
1/13/20265.19 EUR
1/12/20265.24 EUR
1/9/20265.30 EUR
1/8/20265.33 EUR
1/7/20265.34 EUR
1/6/20265.33 EUR
1/5/20265.22 EUR
1/2/20265.16 EUR
12/31/20255.16 EUR
12/30/20255.11 EUR
12/29/20255.15 EUR
12/24/20255.21 EUR
12/23/20255.10 EUR
12/22/20255.07 EUR
12/19/20254.97 EUR
12/18/20254.97 EUR
12/17/20254.92 EUR
12/16/20254.88 EUR
12/15/20254.85 EUR
12/12/20254.81 EUR
12/11/20254.80 EUR
12/10/20254.72 EUR
12/9/20254.71 EUR
12/8/20254.67 EUR
12/5/20254.75 EUR
12/4/20254.81 EUR
12/3/20254.77 EUR
12/2/20254.75 EUR
12/1/20254.74 EUR
11/28/20254.71 EUR
11/27/20254.70 EUR
11/26/20254.65 EUR
11/25/20254.65 EUR
11/24/20254.61 EUR
11/21/20254.59 EUR
11/20/20254.60 EUR
11/19/20254.62 EUR
11/18/20254.59 EUR
11/17/20254.60 EUR
11/14/20254.59 EUR
11/13/20254.62 EUR
11/12/20254.56 EUR
11/11/20254.49 EUR
11/10/20254.43 EUR
11/7/20254.38 EUR
11/6/20254.40 EUR
11/5/20254.47 EUR
11/4/20254.41 EUR
11/3/20254.44 EUR
10/31/20254.43 EUR
10/30/20254.46 EUR
10/29/20254.49 EUR
10/28/20254.50 EUR
10/27/20254.49 EUR
10/24/20254.47 EUR
10/23/20254.52 EUR
10/22/20254.51 EUR
10/21/20254.48 EUR
10/20/20254.47 EUR
10/17/20254.45 EUR
10/16/20254.47 EUR
10/15/20254.42 EUR
10/14/20254.38 EUR
10/13/20254.41 EUR
10/10/20254.37 EUR
10/9/20254.40 EUR
10/8/20254.40 EUR
10/7/20254.35 EUR
10/6/20254.35 EUR
10/3/20254.37 EUR
10/2/20254.35 EUR
10/1/20254.33 EUR
9/29/20254.29 EUR
9/26/20254.19 EUR
9/25/20254.20 EUR
9/24/20254.22 EUR
9/23/20254.22 EUR
9/22/20254.23 EUR
9/19/20254.22 EUR
9/18/20254.18 EUR
9/17/20254.16 EUR
9/16/20254.22 EUR
9/15/20254.26 EUR
9/12/20254.30 EUR
9/11/20254.29 EUR
9/10/20254.28 EUR
9/9/20254.27 EUR
9/8/20254.32 EUR
9/5/20254.30 EUR
9/4/20254.30 EUR
9/3/20254.20 EUR
9/2/20254.15 EUR
9/1/20254.20 EUR
8/29/20254.20 EUR
8/28/20254.22 EUR
8/27/20254.18 EUR
8/26/20254.20 EUR
8/25/20254.21 EUR
8/22/20254.26 EUR
8/21/20254.26 EUR
8/20/20254.23 EUR
8/19/20254.23 EUR
8/18/20254.22 EUR
8/15/20254.21 EUR
8/14/20254.22 EUR
8/13/20254.21 EUR
8/12/20254.21 EUR
8/11/20254.23 EUR
Access this data via the Eulerpool API
Get Free API Key

Faes Farma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
451.17 M EUR
81.22 M EUR
91.90 M EUR
Jan 1, 2024
493.65 M EUR
107.08 M EUR
111.36 M EUR
Jan 1, 2025
610.46 M EUR
76.26 M EUR
79.63 M EUR
Jan 1, 2026 (e)
758.51 M EUR
157.00 M EUR
99.42 M EUR
Jan 1, 2027 (e)
793.00 M EUR
164.14 M EUR
110.14 M EUR
Jan 1, 2028 (e)
854.16 M EUR
176.80 M EUR
124.98 M EUR
Jan 1, 2029 (e)
921.13 M EUR
190.66 M EUR
145.29 M EUR
Jan 1, 2030 (e)
996.80 M EUR
206.32 M EUR
165.60 M EUR

Faes Farma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 10:41 AM
 
REVENUEM EUR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM EUR
EBITM EUR
EBIT MARGIN%
NET INCOMEM EUR
NET INCOME GROWTH%
DIV.EUR
DIV. GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
204.00228.00274.00324.00357.00380.00398.00438.00451.00493.00610.00758.00793.00854.00921.00996.00
6.8111.7620.1818.2510.196.444.7410.052.979.3123.7324.264.627.697.858.14
65.2066.2364.9662.9663.5962.8963.3264.3865.8566.1337.3837.3837.3837.3837.3837.38
133.00151.00178.00204.00227.00239.00252.00282.00297.00326.00228.00283.32296.40319.20344.24372.28
41.0047.0050.0062.0078.0085.0093.0079.0081.00107.0076.00157.00164.00176.00190.00206.00
20.1020.6118.2519.1421.8522.3723.3718.0417.9621.7012.4620.7120.6820.6120.6320.68
30.0036.0042.0051.0063.0072.0082.0089.0091.00111.0079.0099.00110.00124.00145.00165.00
20.0020.0016.6721.4323.5314.2913.898.542.2521.98-28.8325.3211.1112.7316.9413.79
0.090.110.120.140.160.190.200.040.160.160.180.180.180.18––
-10.0022.229.0916.6714.2918.755.26-80.00275.00–20.00–––––
244.72255.97258.06266.03273.84284.73295.17308.84313.63312.46311.27311.27311.27311.27311.27311.27
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Faes Farma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Faes Farma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Faes Farma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Faes Farma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Faes Farma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Faes Farma stock margins

The Faes Farma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Faes Farma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Faes Farma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
63.33 %
23.48 %
20.67 %
Jan 1, 2022
64.28 %
18.09 %
20.40 %
Jan 1, 2023
65.86 %
18.00 %
20.37 %
Jan 1, 2024
66.15 %
21.69 %
22.56 %
Jan 1, 2025
37.42 %
12.49 %
13.04 %
Jan 1, 2026 (e)
37.42 %
20.70 %
13.11 %
Jan 1, 2027 (e)
37.42 %
20.70 %
13.89 %
Jan 1, 2028 (e)
37.42 %
20.70 %
14.63 %

Faes Farma Stock Revenue, EBIT, Earnings per Share

The Faes Farma earnings per share therefore indicates how much revenue Faes Farma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
1.35 EUR
0.32 EUR
0.28 EUR
Jan 1, 2022
1.42 EUR
0.26 EUR
0.29 EUR
Jan 1, 2023
1.44 EUR
0.26 EUR
0.29 EUR
Jan 1, 2024
1.58 EUR
0.34 EUR
0.36 EUR
Jan 1, 2025
1.96 EUR
0.25 EUR
0.26 EUR
Jan 1, 2026 (e)
2.43 EUR
0.50 EUR
0.32 EUR
Jan 1, 2027 (e)
2.54 EUR
0.53 EUR
0.35 EUR
Jan 1, 2028 (e)
2.73 EUR
0.57 EUR
0.40 EUR

Faes Farma business model & stock analysis

The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market.

Faes Farma SWOT Analysis

Strengths

1. Strong brand reputation: Faes Farma SA has established itself as a reputable pharmaceutical company.

2. Diverse product portfolio: The company offers a wide range of pharmaceutical products, catering to various medical needs.

3. Technological innovation: Faes Farma SA invests in research and development to develop advanced healthcare solutions.

Weaknesses

1. Dependence on specific markets: The company's revenue heavily relies on specific geographical areas, making it vulnerable to market fluctuations.

2. Limited international presence: Faes Farma SA has a limited global reach compared to its competitors.

3. Higher production costs: The company faces challenges in maintaining cost-effectiveness due to higher production costs compared to some competitors.

Opportunities

1. Emerging markets: Faes Farma SA can expand its presence in growing markets, such as Asia and Latin America, to increase its market share.

2. Growing demand for personalized medicine: The company can capitalize on the increasing demand for customized healthcare solutions by developing personalized medicines.

3. Strategic partnerships: Faes Farma SA can form alliances with other pharmaceutical companies or healthcare providers to enhance its distribution network and access new markets.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share.

2. Stringent regulations: Compliance with stringent regulatory requirements can pose challenges for Faes Farma SA, affecting its product development timelines and profitability.

3. Economic uncertainty: Fluctuations in the global economy can impact consumer spending on healthcare products and affect the company's financial performance.

Faes Farma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Faes Farma historical P/E ratio, EBIT multiple, and P/S ratio

Faes Farma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Faes Farma shares outstanding

The number of shares of Faes Farma was 311.27 M in 2025. This indicates how many shares Faes Farma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
295.17 M Stocks
Jan 1, 2022
308.84 M Stocks
Jan 1, 2023
313.63 M Stocks
Jan 1, 2024
312.46 M Stocks
Jan 1, 2025
311.27 M Stocks
Jan 1, 2026 (e)
311.27 M Stocks
Jan 1, 2027 (e)
311.27 M Stocks
Jan 1, 2028 (e)
311.27 M Stocks

Faes Farma stock splits

In Faes Farma's history, there have been no stock splits.

Faes Farma Dividend History

37 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.04EURYTD—1×
Jan 8, 20260.04EUR↓ 70.3%1/1
20250.18EUR↑ 15.5%2×
Jan 9, 20250.04EUR↓ 64.7%1/2
Jul 3, 20250.14EUR↑ 236.6%2/2
20240.16EUR 0.0%2×
20230.16EUR↑ 342.9%2×
20220.04EUR↓ 82.6%1×
20210.20EUR↑ 4.1%2×
20200.19EUR↑ 17.7%2×
20190.16EUR↑ 18.8%2×
20180.14EUR↑ 16.9%2×
20170.12EUR↑ 10.8%2×

Faes Farma dividend history and estimates

In 2025, Faes Farma paid a dividend amounting to 0.18 EUR. Dividend means that Faes Farma distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2021
0.20 EUR
0.00 EUR
0.00 EUR
Jan 1, 2022
0.04 EUR
0.00 EUR
0.00 EUR
Jan 1, 2023
0.16 EUR
0.00 EUR
0.00 EUR
Jan 1, 2024
0.16 EUR
0.00 EUR
0.00 EUR
Jan 1, 2025
0.18 EUR
0.00 EUR
0.00 EUR
Jan 1, 2026 (e)
0.00 EUR
0.18 EUR
0.00 EUR
Jan 1, 2027 (e)
0.00 EUR
0.18 EUR
0.00 EUR
Jan 1, 2028 (e)
0.00 EUR
0.18 EUR
0.00 EUR

Faes Farma dividend payout ratio

In 2025, Faes Farma had a payout ratio of 69.97%. The payout ratio indicates the percentage of the company's profits that Faes Farma distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
71.55 %
Jan 1, 2022
11.67 %
Jan 1, 2023
52.47 %
Jan 1, 2024
43.49 %
Jan 1, 2025
69.97 %
Jan 1, 2026 (e)
56.25 %
Jan 1, 2027 (e)
50.78 %
Jan 1, 2028 (e)
44.75 %

Current Faes Farma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
60.00 % (6)
Hold
30.00 % (3)
Sell
10.00 % (1)
12M Price Target
5.61
Last Price
4.52
Currency
EUR
12M Return Potential
24.12 %
LTM Return
0 %

Faes Farma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
10/24/2019-EUR-84.24 MEUR-2019 Q3
7/24/2019-EUR-94.39 MEUR-2019 Q2
4/29/2019-EUR-98.96 MEUR-2019 Q1
2/24/20100.01EUR-49.23 MEUR-2009 Q4
11/12/2008-EUR-42.02 MEUR-2008 Q3
8/28/2008-EUR-46.69 MEUR-2008 Q2
5/7/2008-EUR-51.76 MEUR-2008 Q1
2/29/20080.00EUR-45.67 MEUR-2007 Q4
11/15/2007-EUR-43.64 MEUR-2007 Q3
7/26/2007-EUR-51.36 MEUR-2007 Q2

EESG©

Eulerpool ESG Scorecard© for the Faes Farma stock

65/100
66
Environment
99
Social
31
Governance
E

Environment

20
Scope 1 - Direct Emissions4,965
Scope 2 - Indirect emissions from purchased energy2,615
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions7,580
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees54
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Faes Farma shareholder structure

% Name
8.14706%
Alantra Asset Management SGIIC, S.A.
Alantra Asset Management SGIIC, S.A.
6.33548%
Indumenta Pueri, S.L.
Indumenta Pueri, S.L.
5.08082%
Urrutia Vallejo (Victor)
Urrutia Vallejo (Victor)
3.37647%
Asua Inversiones SL
Asua Inversiones SL
1.36921%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
1.29018%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC

Faes Farma Beneficial Ownership Filings (SEC 13D/G)

Free Float
69.7%
Float Shares
-
Shares Outstanding
-

Faes Farma Executives and Management Board

25 members · avg. age 66 · 36 % women

DC

Don Eduardo Recoder De La Cuadra

Chief Executive Officer, Executive Director · since 2024

526,000.00 EUR

Management

DU

Don Valentin Ruiz Unamunzaga

Chief Financial Officer · since 2024

–
DA

Don Carlos Gutierrez Aguero

Chief People Officer

–
DL

Don Jaime Lopez

Global Head - IT

–
DF

Don Alberto Fernandez Fernandez

Chief Marketing and Portfolio Strategy Officer

–
DN

Dna. Isabel Najera

Chief Scientific and Medical Officer

–
DZ

Dna. Mariana Soroa Zubiria

Chief GRC & Internal Audit Officer · since 2024

–

Board of Directors

DA

Don Mariano Ucar Angulo

Chairman of the Board, Other External Director · since 1991

3.34 M EUR
DC

Dna. Belen Amatriain Corbi (66)

Independent Director

146,000.00 EUR
DS

Dna. Maria Eugenia Zugaza Salazar

Independent Director

146,000.00 EUR
DP

Don Enrique Linares Plaza

Lead Independent Director

121,000.00 EUR
DL

Dna. Nuria Pascual Lapena

Independent Director

117,000.00 EUR
DP

Dna. Carmen Basagoiti Pastor

Proprietary Director

97,000.00 EUR

Frequently asked questions about Faes Farma

The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.

Faes Farma SA is primarily active in the pharmaceutical industry.

Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.

Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.

Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.

Faes Farma SA is primarily present in Spain and Portugal.

Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.

Analysts currently set an average price target of 5.36 EUR for the Faes Farma stock (median: 5.61 EUR), implying +18.5 % versus the latest price. The consensus is based on 10 analyst ratings.

Faes Farma Analyst Price Targets 2026

10 analysts currently rate the Faes Farma stock: 6 recommend buying, 3 holding and 1 selling. For 2026, analysts expect Faes Farma to generate revenue of 758.51 M EUR and earnings per share of 0.32 EUR.

Faes Farma Analyst Price Targets 2026

The Faes Farma share (FAE.MC) is listed on 7 stock exchanges, including: Frankfurt (FFEA.F), München (FFEA.MU), Düsseldorf (FFEA.DU), London (0K9H.L).

Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.

The expected revenue of Faes Farma is 758.51 M EUR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Faes Farma is 99.42 M EUR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Faes Farma is currently 14.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Faes Farma stock.

The price-to-sales ratio (P/S) of Faes Farma is currently 1.85. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Faes Farma stock.

The Eulerpool Quality Score for Faes Farma is 7/10.

The ISIN of Faes Farma is ES0134950F36. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Faes Farma is A0MKAC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Faes Farma is FAE.MC. The ticker symbol is used to trade Faes Farma shares on the stock exchange.

Over the past 12 months, Faes Farma paid a dividend of 0.18 EUR . This corresponds to a dividend yield of about 3.96 %. For the coming 12 months, Faes Farma is expected to pay a dividend of 0.18 EUR.

The current dividend yield of Faes Farma is 3.96 %.

Faes Farma pays a dividend, distributed in the months of , , , .

Faes Farma paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 0.18 EUR are expected. This corresponds to a dividend yield of 3.96 %.

Faes Farma is assigned to the 'Health' sector.

To receive the latest dividend of Faes Farma from amounting to 0.04 EUR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Faes Farma distributed 0.16 EUR as dividends.

The dividends of Faes Farma are distributed in EUR.

All fundamentals and in-depth analysis of Faes Farma

Our stock analysis for Faes Farma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Faes Farma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Faes Farma Stock
Faes Farma Revenue→
Faes Farma Stock
Faes Farma Net Income→
Faes Farma Stock
Faes Farma P/E→
Faes Farma Stock
Faes Farma P/S→
Faes Farma Stock
Faes Farma EBIT→
Faes Farma Stock
Faes Farma Dividend→
Faes Farma Stock
Faes Farma Directors Dealings→
Faes Farma Stock
Faes Farma Stocks→
Faes Farma Stock
Faes Farma Market capitalization→
Faes Farma Stock
Faes Farma Debt→
Faes Farma Stock
Faes Farma Liabilities→
Faes Farma Stock
Faes Farma Equity→
Faes Farma Stock
Faes Farma AAQS→
Faes Farma Stock
Faes Farma Employees→
Faes Farma Stock
Faes Farma ROE→
Faes Farma Stock
Faes Farma ROA→
Faes Farma Stock
Faes Farma ROCE→
Faes Farma Stock
Faes Farma News→
Faes Farma Stock
Faes Farma Analyst Price Targets→

Health Stocks

FagronFabino EnterprisesFalco Holdings CoF D CFamiCordEZZ Life Science HoldingsFamily Care HospitalsezCaretech CoFamon Awal Bros Sedaya Tbk PTEyePointFaron Pharmaceuticals OyEyeGeneAll Stocks A–Z →